Ianalumab: tested on its own
25 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenRecruitingNCT07621809Phase 3Report a problem
- Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)RecruitingNCT06711887Phase 3Report a problem
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).RecruitingNCT06133972Phase 3Report a problem
- Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)CompletedNCT02962895Phase 2Results postedReport a problem
- PD of VAY736 in Patients With Primary Sjögren's SyndromeCompletedNCT02149420Phase 2Results postedReport a problem
- A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple SclerosisTerminatedNCT02038049Phase 2Results postedReport a problem
- Study of Efficacy and Safety of VAY736 in Patients With Pemphigus VulgarisTerminatedNCT01930175Phase 2Results postedReport a problem
- Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabWithdrawnNCT07039422Phase 2Report a problem
- A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisActive, not recruitingNCT06470048Phase 2Report a problem
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune DiseasesWithdrawnNCT06411639Phase 1Report a problem
- Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseaseActive, not recruitingNCT06293365Phase 2Report a problem
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.Active, not recruitingNCT05985915Phase 3Report a problem
- A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of TherapiesActive, not recruitingNCT05885555Phase 2Report a problem
- A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaActive, not recruitingNCT05648968Phase 3Report a problem
- Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Active, not recruitingNCT05639114Phase 3Report a problem
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Active, not recruitingNCT05624749Phase 3Report a problem
- Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeCompletedNCT05350072Phase 3Report a problem
- Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeActive, not recruitingNCT05349214Phase 3Report a problem
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisActive, not recruitingNCT05126277Phase 3Report a problem
- Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.CompletedNCT05124925Phase 2Report a problem
- Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid ArthritisCompletedNCT03574545Phase 1Report a problem
- ADCC Mediated B-Cell dEpletion and BAFF-R BlockadeCompletedNCT03217422Phase 2/3Report a problem
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis PatientsCompletedNCT02675803Phase 1Report a problem
- Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's SyndromeWithdrawnNCT02495129Phase 1/2Report a problem
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL PatientsTerminatedNCT02137889Phase 1Report a problem